Zafgen, Inc. Email Format
BiotechnologyMassachusetts, United States11-50 Employees
Zafgen, Inc. is a clinical-stage biotechnology company focused on therapies for metabolic diseases based on MetAP2 biology. It has studied MetAP2 inhibitors across a spectrum of metabolic disorders, with current emphasis on type 2 diabetes, Prader-Willi syndrome, and other serious obesity-related conditions. The company seeks to translate this biology into treatments that can benefit patients affected by these conditions. Headquartered in Boston, Massachusetts, Zafgen operates with a smaller, specialized team. A notable 2023 development was the appointment of Gopi Shankar as Chief Development Officer, underscoring a focus on advancing development efforts.